Needham & Company LLC Forecasts Strong Price Appreciation for NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics (NASDAQ:NEO) had its price objective upped by research analysts at Needham & Company LLC from $14.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. Needham & Company LLC’s target price indicates a potential upside of 46.20% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, December 29th. Zacks Research upgraded shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 12th. Leerink Partners set a $14.00 target price on NeoGenomics in a research report on Tuesday, October 28th. Finally, TD Cowen reissued a “buy” rating on shares of NeoGenomics in a report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, NeoGenomics presently has a consensus rating of “Hold” and a consensus target price of $11.57.

NeoGenomics Stock Performance

Shares of NEO opened at $10.26 on Tuesday. The stock has a 50-day moving average of $12.13 and a two-hundred day moving average of $10.11. The stock has a market cap of $1.33 billion, a P/E ratio of -12.21 and a beta of 1.58. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.62 and a current ratio of 4.26. NeoGenomics has a one year low of $4.72 and a one year high of $13.74.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, February 17th. The medical research company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The firm had revenue of $190.17 million during the quarter, compared to analyst estimates of $188.25 million. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The business’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.04 EPS. As a group, research analysts predict that NeoGenomics will post -0.2 EPS for the current year.

Insider Transactions at NeoGenomics

In related news, EVP Alicia C. Olivo sold 20,916 shares of the company’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total transaction of $250,992.00. Following the completion of the sale, the executive vice president directly owned 31,083 shares of the company’s stock, valued at approximately $372,996. This represents a 40.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Warren Stone sold 22,128 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total transaction of $276,600.00. Following the transaction, the chief operating officer directly owned 121,631 shares in the company, valued at $1,520,387.50. The trade was a 15.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On NeoGenomics

Hedge funds have recently modified their holdings of the company. First Horizon Corp increased its holdings in shares of NeoGenomics by 52.6% in the fourth quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock valued at $30,000 after buying an additional 865 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of NeoGenomics by 110.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 1,556 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in shares of NeoGenomics in the 4th quarter valued at about $39,000. Aster Capital Management DIFC Ltd increased its stake in shares of NeoGenomics by 42.5% in the third quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock worth $26,000 after acquiring an additional 997 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in shares of NeoGenomics by 77.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 3,466 shares of the medical research company’s stock valued at $42,000 after buying an additional 1,515 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting NeoGenomics

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q4 revenue and adjusted EPS beat consensus — NeoGenomics reported Q4 revenue of $190.17M (above estimates) and an adjusted EPS beat vs. consensus, showing year‑over‑year revenue growth of ~10.6%. This is the core fundamental positive that supports longer‑term growth expectations. Press Release
• Positive Sentiment: Growth initiatives highlighted — management reiterated a FY2026 revenue target of $793M–$801M and emphasized traction for RaDaR ST and PanTracer programs, which investors view as multi‑year growth drivers if adoption continues. Article
• Positive Sentiment: Analyst upgrade/target lift — Needham raised its price target from $14 to $15 and maintained a Buy, signaling some analysts see meaningful upside from current levels. Benzinga
• Neutral Sentiment: Management outreach to investors — NeoGenomics will present at TD Cowen and Leerink healthcare conferences, which could provide more color and potentially move the stock as analysts and investors parse guidance and product updates. Conference Notice
• Negative Sentiment: Conflicting/negative EPS reporting in some transcripts — while company releases and some outlets show an adjusted EPS beat, at least one earnings transcript/coverage reported a materially negative EPS figure (GAAP), creating market confusion and selling pressure. Investors reacted to the mixed messaging. Transcript (InsiderMonkey)
• Negative Sentiment: Shares dropped despite the beat — multiple reports note the stock fell sharply after the print, suggesting the market focused on margin/GAAP weakness, guidance ambiguity, and higher trading volume rather than the top‑line beat. MSN
• Negative Sentiment: Thin/unclear EPS guidance and profitability metrics — the company’s FY2026 revenue range is roughly in line with consensus but EPS guidance was vague/absent in public summaries, and NeoGenomics still shows negative net margin and negative ROE on a reported basis, leaving profitability execution as a near‑term risk. Slide Deck / Press Materials

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.